{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:12:33Z","timestamp":1790298753316,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T00:00:00Z","timestamp":1458518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T00:00:00Z","timestamp":1458518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1038\/bmt.2016.66","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T14:54:20Z","timestamp":1458572060000},"page":"1087-1092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation"],"prefix":"10.1038","volume":"51","author":[{"given":"D","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P J","family":"Oefner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Dettmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hiergeist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Koestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"St\u00e4mmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Holler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,21]]},"reference":[{"key":"BFbmt201666_CR1","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"JL Ferrara","year":"2009","unstructured":"Ferrara JL, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 373: 1550\u20131561.","journal-title":"Lancet"},{"key":"BFbmt201666_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/jnci\/52.2.401","volume":"52","author":"DW van Bekkum","year":"1974","unstructured":"van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D . Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974; 52: 401\u2013404.","journal-title":"J Natl Cancer Inst"},{"key":"BFbmt201666_CR3","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1172\/JCI78366","volume":"124","author":"MJ Blaser","year":"2014","unstructured":"Blaser MJ . The microbiome revolution. J Clin Invest 2014; 124: 4162\u20134165.","journal-title":"J Clin Invest"},{"key":"BFbmt201666_CR4","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1084\/jem.20112408","volume":"209","author":"RR Jenq","year":"2012","unstructured":"Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012; 209: 903\u2013911.","journal-title":"J Exp Med"},{"key":"BFbmt201666_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bbmt.2014.01.030","volume":"20","author":"E Holler","year":"2014","unstructured":"Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic SCT: Loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal GvHD. Biol Blood Marrow Transplant 2014; 20: 640\u2013645.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201666_CR6","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2014-02-554725","volume":"124","author":"Y Taur","year":"2014","unstructured":"Taur Y, Jenq RR, Perales MA, Littmann ER, Morjaria S, Ling L et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014; 124: 1174\u20131182.","journal-title":"Blood"},{"key":"BFbmt201666_CR7","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1182\/blood-2015-04-638858","volume":"126","author":"D Weber","year":"2015","unstructured":"Weber D, Oefner PJ, Hiergeist A, Koestler J, Gessner A, Weber M et al. Low urinary indoxyl sulfate levels early after ASCT reflect a disrupted microbiome and are associated with poor outcome. Blood 2015; 126: 1723\u20131728.","journal-title":"Blood"},{"key":"BFbmt201666_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000081990","volume":"51","author":"C Scarpignato","year":"2005","unstructured":"Scarpignato C, Pelosini I . Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005; 51: 36\u201366.","journal-title":"Chemotherapy"},{"key":"BFbmt201666_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1517\/17425250902973695","volume":"5","author":"V Ojetti","year":"2009","unstructured":"Ojetti V, Lauritano EC, Barbaro F, Migneco A, Ainora ME, Fontana L et al. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol 2009; 5: 675\u2013682.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"BFbmt201666_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/MOG.0b013e328333dc8d","volume":"26","author":"HL Koo","year":"2010","unstructured":"Koo HL, DuPont HL . Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010; 26: 17\u201325.","journal-title":"Curr Opin Gastroenterol"},{"key":"BFbmt201666_CR11","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/jac\/dkq345","volume":"65","author":"S Maccaferri","year":"2010","unstructured":"Maccaferri S, Vitali B, Klinder A, Kolida S, Ndagijimana M, Laghi L et al. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother 2010; 65: 2556\u20132565.","journal-title":"J Antimicrob Chemother"},{"key":"BFbmt201666_CR12","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1182\/blood.V93.10.3267.410k22_3267_3275","volume":"93","author":"DW Beelen","year":"1999","unstructured":"Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW . Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93: 3267\u20133275.","journal-title":"Blood"},{"key":"BFbmt201666_CR13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/sj.bmt.1704448","volume":"33","author":"M Kreutz","year":"2004","unstructured":"Kreutz M, Eissner G, Hahn J, Andreesen R, Drobnik W, Holler E . Variations in 1 alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 serum levels during allogeneic bone marrow transplantation. Bone Marrow transplantation 2004; 33: 871\u2013873.","journal-title":"Bone Marrow transplantation"},{"key":"BFbmt201666_CR14","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3748\/wjg.v20.i5.1192","volume":"20","author":"GL Hold","year":"2014","unstructured":"Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I . Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol 2014; 20: 1192\u20131210.","journal-title":"World J Gastroenterol"},{"key":"BFbmt201666_CR15","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/ajg.2015.149","volume":"110","author":"KL Kolho","year":"2015","unstructured":"Kolho KL, Korpela K, Jaakkola T, Pichai MV, Zoetendal EG, Salonen A et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol 2015; 110: 921\u2013930.","journal-title":"Am J Gastroenterol"},{"key":"BFbmt201666_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1182\/blood-2011-12-401166","volume":"120","author":"Y Eriguchi","year":"2012","unstructured":"Eriguchi Y, Takashima S, Oka H, Shimoji S, Nakamura K, Uryu H et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of alpha-defensins. Blood 2012; 120: 223\u2013231.","journal-title":"Blood"},{"key":"BFbmt201666_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11882-015-0562-9","volume":"15","author":"JJ Hansen","year":"2015","unstructured":"Hansen JJ . Immune responses to intestinal microbes in inflammatory bowel diseases. Curr Allergy Asthma Rep 2015; 15: 61.","journal-title":"Curr Allergy Asthma Rep"},{"key":"BFbmt201666_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.4161\/gmic.32130","volume":"5","author":"J Gao","year":"2014","unstructured":"Gao J, Gillilland MG 3rd, Owyang C . Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship. Gut Microbes 2014; 5: 571\u2013575.","journal-title":"Gut Microbes"},{"key":"BFbmt201666_CR19","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/j.1365-2036.2006.02879.x","volume":"23","author":"C Prantera","year":"2006","unstructured":"Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006; 23: 1117\u20131125.","journal-title":"Aliment Pharmacol Ther"},{"key":"BFbmt201666_CR20","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1185\/030079905X53252","volume":"21","author":"I Shafran","year":"2005","unstructured":"Shafran I, Johnson LK . An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin 2005; 21: 1165\u20131169.","journal-title":"Curr Med Res Opin"},{"key":"BFbmt201666_CR21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijantimicag.2009.11.013","volume":"35","author":"ZD Jiang","year":"2010","unstructured":"Jiang ZD, Ke S, Dupont HL . Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents 2010; 35: 278\u2013281.","journal-title":"Int J Antimicrob Agents"},{"key":"BFbmt201666_CR22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1128\/AAC.00691-09","volume":"54","author":"EL Brown","year":"2010","unstructured":"Brown EL, Xue Q, Jiang ZD, Xu Y, Dupont HL . Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother 2010; 54: 388\u2013396.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFbmt201666_CR23","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.mayocp.2015.04.016","volume":"90","author":"HL DuPont","year":"2015","unstructured":"DuPont HL . Therapeutic effects and mechanisms of action of rifaximin in gastrointestinal diseases. Mayo Clin Proc 2015; 90: 1116\u20131124.","journal-title":"Mayo Clin Proc"},{"key":"BFbmt201666_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2174\/1389557515666150722105705","volume":"16","author":"SA Hirota","year":"2015","unstructured":"Hirota SA . Understanding the molecular mechanisms of rifaximin in the treatment of gastrointestinal disorders\u2014a focus on the modulation of host tissue function. Mini Rev Med Chem 2015; 16: 206\u2013217.","journal-title":"Mini Rev Med Chem"},{"key":"BFbmt201666_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.tips.2012.03.003","volume":"33","author":"J Cheng","year":"2012","unstructured":"Cheng J, Shah YM, Gonzalez FJ . Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci 2012; 33: 323\u2013330.","journal-title":"Trends Pharmacol Sci"},{"key":"BFbmt201666_CR26","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1097\/MPH.0b013e31827e56af","volume":"35","author":"M Qayed","year":"2013","unstructured":"Qayed M, Langston A, Chiang KY, August K, Hilinski JA, Cole CR et al. Rifaximin for preventing acute graft-versus-host disease: impact on plasma markers of inflammation and T-cell activation. J Pediatr Hematol Oncol 2013; 35: e149\u2013e152.","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201666.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201666","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201666.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:20:11Z","timestamp":1648063211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,21]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["BFbmt201666"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.66","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,21]]},"assertion":[{"value":"22 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}